肿瘤细胞治疗研究
ALL SOURCES
Phase I trial of IL13Rα2-targeted CAR-T cell therapy for recurrent malignant glioma: clinical results and pharmacokinetics.
静脉注射 IL13R 2 靶向 CAR-T 疗法耐受性良好，并显示出初步安全性。需要进一步研究以优化给药方案和预处理方案，并确定用于疗效评估的探索性生物标志物。
High-risk features in adult patients with B-cell acute lymphoblastic leukemia: redefining risk in the era of targeted immunotherapy.
成人B细胞急性淋巴细胞白血病（B-ALL）的治疗格局随着靶向免疫治疗药物的引入已发生实质性变化。
Real-World Outcomes of Tisagenlecleucel Versus Standard-of-Care Salvage Chemotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Propen
在这项来自亚洲的真实世界倾向性评分匹配比较中，tisagenlecleucel 在韩国 R/R DLBCL 患者中显示出优于 SOC 挽救化疗的生存和缓解结局，支持其作为 3L 治疗标准方案的地位。
Immunosenescence and Cancer: Cellular Aging Programs That Reshape Antitumor Immunity.
免疫衰老是指与年龄相关的免疫能力下降，部分由衰老相关分泌表型（SASP）驱动，后者维持慢性低度炎症（“炎症衰老”）。
PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells.
靶向CD19的嵌合抗原受体（CAR）T细胞已成为复发和难治性B细胞恶性肿瘤患者的重要治疗选择。
Outcome of second allogeneic hematopoietic cell transplantation in adult patients with relapsed B-cell acute lymphoblastic leukemia in the era of new
费城染色体（Ph）阴性B-ALL（n = 45）接受新型药物治疗，与常规化疗相比显示出改善的生存结局（中位生存期29.6 vs.
Economic Evaluation of Axicabtagene Ciloleucel as a Second-Line Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in South Korea: A Cost-U
Axi-cel作为复发或难治性DLBCL的二线治疗，在生存期和质量调整生命年方面提供了有意义的获益，与韩国SoC相比，似乎是一种具有成本效益的替代方案。
Insights on the Role of Sialic Acids in Acute Lymphoblastic Leukemia in Children.
唾液酸是细胞表面糖蛋白或糖脂上至关重要的末端糖。
Pre-Transplant Natural Killer Cell Activity Predicts Survival and Tumor Recurrence After Living Donor Liver Transplantation.
结果：被归类为高 NK 活性（10 pg/mL）的患者相比低活性患者，总生存期显著更好（log-rank p = 0.032）。
The infusion of ex vivo, interleukin-15 and -21-activated donor NK cells after haploidentical HCT in high-risk AML and MDS patients-a randomized trial
76例可评估患者（年龄21-70岁）被随机分配接受单倍体HCT后DNKI治疗（N=40）或不接受（N=36）。
MEMBER ACCOUNT
登录成功会直接打开下一页。
